Novo Nordisk plans to seek U.S. approval of its high-dose weight loss injections

Novo Nordisk plans to apply to the U.S. Food and Drug Administration (FDA) to approve the high-dose version of Wegovy, aiming to compete with Eli Lilly's Zepbound in the obesity market. Chief Science Officer Martin Holst Lange said the high-dose version has similar weight loss potential, giving patients an alternative. The statement was announced at the European Association for Research on Diabetes (EAD) in Vienna.